Moreover, silibinin mitigates immunosuppression and inhibits tumor progression by limiting PD-L1 protein expression in lung cancer (A549, H292, and H460), papillary thyroid cancer (TPC-1), and nasopharyngeal carcinoma (C666-1) cells [889, 892, 897]. This evidence concerns the gene CD274 and lung cancer.